The company's common stock is listed on the NASDAQ Stock Market under the symbol "ICAD".
Investor Presentation
To access a copy of the investor presentation, please see below.
Quick Links
Investor Relations
Media Inquiries
Featuring presentations by Key Opinion Leaders Per Hall, MD, PhD (Karolinska Institutet), Axel Gräwingholt, MD (Radiologie am Theater), Joshua A. Nepute, MD (Indiana University Health-Arnett), and Emily F. Conant, MD (University of Pennsylvania Perelman School of Medicine) who will discuss the current landscape for digital breast tomosynthesis (DBT) and the potential for iCAD's recently introduced ProFound AI Risk, the first and only commercially available clinical decision support tool that provides an accurate two-year breast cancer risk estimation based solely on a screening mammogram.
Featuring presentations by Key Opinion Leaders (KOLs) Janie Grumley, MD, FACS (John Wayne Cancer Center), Té Vuong, MD, FRCP (McGill University & Jewish General Hospital), and Santosh Kesari, MD, PhD (John Wayne Cancer Center), who discuss the current treatment landscape and unmet medical need in treating patients with cancers such as breast, rectal, and glioblastoma multiforme. Also highlighted will be recently presented positive clinical data for Xoft® Brain IORT as viable treatment option for glioblastoma multiforme.
iCAD, Inc.
603.882.5200
pr@icadmed.com
iCAD is committed to corporate sustainability and to making a difference for our environment.
Recent Press Releases
February 24, 2021
iCAD Reports Financial Results for Fourth Quarter and Year Ended December 31, 2020
February 19, 2021
iCAD to Report Fourth Quarter 2020 Financial Results on Wednesday, February 24
February 16, 2021
iCAD to Participate in the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
January 19, 2021
iCAD to Participate in B. Riley Securities Virtual Oncology Investor Conference
January 6, 2021
iCAD to Participate in the LifeSci Partners 10th Annual Healthcare Corporate Access Event
Recent Events and Webcasts
February 24, 20214:30 pm ET
iCAD to Report Fourth Quarter 2020 Financial Results
February 18, 20214:30 pm ET
iCAD to Participate in the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
January 20, 202111:30 am ET
iCAD to Participate in the LifeSci Partners 10th Annual Healthcare Corporate Access Event
January 6-8 and 11-14, 20214:30 pm ET
iCAD to Participate in the LifeSci Partners 10th Annual Healthcare Corporate Access Event
November 5, 20204:30 pm ET
iCAD To Report Third Quarter 2020 Financial Results
Resources
Precise and Powerful Healthcare Solutions
© 2020, iCAD Inc. All rights reserved. iCAD, the iCAD logo, PowerLook, ProFound AI, ProFound, Xoft, the Xoft logo, Axxent, Electronic Brachytherapy System and eBx are trademarks of iCAD, Inc. Reproduction of any of the material contained herein in any format or media without the express written permission of iCAD, Inc. is prohibited.
iCAD, Inc. an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer. The core business delivers innovative cancer detection and radiation therapy solutions and services that enable clinicians to find and treat cancers earlier and while enhancing patient care. The comprehensive iCAD technology platforms include advanced hardware and software as well as management services designed to support cancer detection (CAD) and radiation therapy (eBx) treatments.